International Edition
Latest News
Health

New Drug May Cure Common Hormonal Cause of High Blood Pressure

Extended aldosterone synthase inhibition (EASI) may provide a lasting cure for hypertension driven by hormone overproduction. A study published in the New England Journal of Medicine indicates that patients treated with the drug baxdrostat for 6 to 12…

New Drug May Cure Common Hormonal Cause of High Blood Pressure

Extended aldosterone synthase inhibition (EASI) may provide a lasting cure for hypertension driven by hormone overproduction.

A study published in the New England Journal of Medicine indicates that patients treated with the drug baxdrostat for 6 to 12 months sustained lower blood pressure for up to two years after discontinuing the medication.

This treatment addresses the root cause of primary aldosteronism, a condition estimated to affect 5% to 10% of patients with high blood pressure. In these cases, benign adrenal gland nodules produce excess aldosterone, signaling the kidneys to retain salt and driving pressure upward.

Baxdrostat, also known as Baxfendy, is the first of this specific class of medication to hit the U.S. market, though other drugs such as lorundrostat are in the pipeline.

“Just under a quarter of the patients came off all treatment and had completely normal blood pressure,” said Prof. Morris Brown, a hypertension specialist at Queen Mary University of London who led the study. “It’s very exciting to see.”

Data showed the primary marker of excess aldosterone production remained 99% lower than pre-treatment levels, with blood pressure readings averaging 25 points lower. By targeting the source of the hormone, EASI treatment aims to reverse the condition entirely, potentially removing the necessity for lifelong daily medication or invasive surgery on the adrenal glands. Previously, surgery to remove the entire gland was the only known cure for primary aldosteronism.

New Drug May Cure Common Hormonal Cause of High Blood Pressure
Photo: theguardian.com

Potential Benefits for Patients

The National Institute for Health and Care Excellence is currently assessing the drug to determine if it can be made available through the NHS by next year. Harvard Medical School’s Professor Mason Freeman, who initiated the original research, said that the findings were “extraordinary and unexpected.”

Professor Freeman said that if these benefits hold up in larger groups, the way doctors diagnose the condition could change substantially. He explained that patients responding well to this treatment might ultimately avoid invasive diagnostic procedures and surgery.

Applying Scientific Insights From Mice

The treatment’s scientific basis stems from a 2005 experiment in mice, which demonstrated that deleting the gene responsible for aldosterone synthase caused the hormone-producing cells to disappear. Professor Morris Brown hypothesized that baxdrostat might trigger a similar process in humans by generating reactive oxygen species that selectively destroy overactive cells.

A Pill That May Cure Hormone-Driven High Blood Pressure — huyền thanh

The Hormonal Mechanism

Prof. Brown suggests that baxdrostat may induce a comparable effect in humans by generating reactive oxygen species that selectively destroy the overactive cells.

“Those oxygen radicals are killing the cells and they disappear,” Prof. Brown said.

The study was conducted across eight centers in the United States. While previous tests of these inhibitors used shorter treatment windows of 6 to 12 weeks, this research observed the effects of 6 to 12 months of administration.

“While duly cautious about our findings because of the pragmatic nature of the study, they were predicted by previous experiments, and longer follow-up may justify a claim that a finite course of medication leads to infinite cure,” Prof. Brown said in a university press release.

Researchers are currently managing a larger prospective clinical trial to determine if prolonged treatment consistently results in the disappearance of aldosterone-producing cells. Brown has generated some extraordinary and unexpected findings.”

Prof. Freeman said that if these benefits are confirmed in broader populations, the clinical approach to diagnosing and treating these patients could change dramatically, potentially allowing patients to avoid invasive diagnostic procedures and surgery.

“EASI-treatment is unlikely to be the elixir for most patients with hypertension,” Prof. Brown said. “But the possibility of tablets achieving a surgical cure has long been a holy grail for this common type of hypertension.”

About the author: Health Desk

Health Desk at Archynewsy.